Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Zou, Jie ^a   Li, Peng ^a   Lu, Fei ^a   Liu, Na ^a   Dai, Jianjian ^a   Ye, Jingjing ^a   Qu, Xun ^a   Sun, Xiulian ^a   Ma, Daoxin ^a   Park, Jino ^b   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresistance; HIF 1 ; Hypoxia; Invasion; Notch1; Proliferation; T cell acute lymphoblastic leukemia

Indexed keywords

DEXAMETHASONE; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HYPOXIA; LEUKEMIA CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JURKAT CELLS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84871821947     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-3     Document Type: Article

References (42)

1. Acute lymphoblastic leukemia. Pui CH, Relling MV, Downing JR, N Engl J Med 2004 350 1535 1548 10.1056/NEJMra023001 15071128 (Pubitemid 38477778)
2. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC, Science 2004 306 269 271 10.1126/science.1102160 15472075 (Pubitemid 39336870)
3. Notch signalling in cancer progression and bone metastasis. Sethi N, Kang Y, Br J Cancer 2011 105 1805 1810 10.1038/bjc.2011.497 22075946
4. The multifaceted role of Notch in cancer. Roy M, Pear WS, Aster JC, Curr Opin Genet Dev 2007 17 52 59 10.1016/j.gde.2006.12.001 17178457 (Pubitemid 46109291)
5. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U, Proc Natl Acad Sci U S A 2008 105 6392 6397 10.1073/pnas.0802047105 18427106 (Pubitemid 351758356)
6. Notch signalling: a simple pathway becomes complex. Bray SJ, Nat Rev Mol Cell Biol 2006 7 678 689 10.1038/nrm2009 16921404 (Pubitemid 44268213)
7. Activating Notch1 mutations in mouse models of T-ALL. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT, Blood 2006 107 781 785 10.1182/blood-2005-06-2553 16166587 (Pubitemid 43076406)
8. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ, Blood 2007 110 278 286 10.1182/blood-2006-08-039883 17363738 (Pubitemid 47026845)
9. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, et al. Nat Med 2009 15 50 58 10.1038/nm.1900 19098907
10. The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA, Blood 2003 102 1634 1640 10.1182/blood-2003-02-0448 12750163 (Pubitemid 37022554)
11. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Hochachka PW, Buck LT, Doll CJ, Land SC, Proc Natl Acad Sci U S A 1996 93 9493 9498 10.1073/pnas.93.18.9493 8790358 (Pubitemid 26296636)
12. Regulation of angiogenesis by hypoxia: role of the HIF system. Pugh CW, Ratcliffe PJ, Nat Med 2003 9 677 684 10.1038/nm0603-677 12778166 (Pubitemid 36749216)
13. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Semenza GL, Annu Rev Cell Dev Biol 1999 15 551 578 10.1146/annurev.cellbio.15.1. 551 10611972 (Pubitemid 32250386)
14. Targeting HIF-1 for cancer therapy. Semenza GL, Nat Rev Cancer 2003 3 721 732 10.1038/nrc1187 13130303 (Pubitemid 37328811)
15. Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, Kamiunten A, Sekine M, Taniguchi Y, Yamamoto S, et al. Leuk Res 2012 36 122 124 10.1016/j.leukres.2012.02.028 22444690
16. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. Tanturli M, Giuntoli S, Barbetti V, Rovida E, Dello Sbarba P, PLoS One 2011 6 17008 10.1371/journal.pone.0017008 21347297
17. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Raetz EA, Bhatla T, Hematology Am Soc Hematol Educ Program 2012 2012 129 136 23233571
18. Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR). Weber A, Taube S, Zur Stadt U, Horstmann M, Krohn K, Bradtke J, Teigler-Schlegel A, Leiblein S, Christiansen H, Exp Hematol Oncol 2012 1 33 10.1186/2162-3619-1- 33 23210797
19. French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P, et al. Exp Hematol Oncol 2012 1 39 10.1186/2162-3619-1-39 23227903
20. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Chen J, Imanaka N, Griffin JD, Br J Cancer 2010 102 351 360 10.1038/sj.bjc.6605486 20010940
21. Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Zhong H, Mabjeesh N, Willard M, Simons J, Cancer Lett 2002 181 233 238 10.1016/S0304-3835(02)00053-8 12175540 (Pubitemid 34518309)
22. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M, Dev Cell 2005 9 617 628 10.1016/j.devcel.2005.09.010 16256737 (Pubitemid 41555144)
23. Lasting longer without oxygen: The influence of hypoxia on Notch signaling. Pear WS, Simon MC, Cancer Cell 2005 8 435 437 10.1016/j.ccr.2005.11. 016 16338655 (Pubitemid 41773445)
24. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G, Clin Cancer Res 2001 7 1661 1668 11410504 (Pubitemid 32708633)
25. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL, Cancer Res 2001 61 1830 1832 11280732 (Pubitemid 32691993)
26. HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Zhang H, Li H, Xi HS, Li S, Blood 2012 119 2595 2607 10.1182/blood-2011-10-387381 22275380
27. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, et al. Am J Pathol 2004 164 1131 1139 10.1016/S0002-9440(10)63200-2 15039201 (Pubitemid 38387779)
28. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP, Oncogene 2006 25 2379 2392 10.1038/sj.onc.1209273 16369494
29. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Ries C, Loher F, Zang C, Ismair MG, Petrides PE, Clin Cancer Res 1999 5 1115 1124 10353746 (Pubitemid 29233227)
30. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF, Br J Haematol 2002 117 835 841 10.1046/j.1365-2141.2002.03510.x 12060118 (Pubitemid 34639244)
31. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G, Leuk Res 2004 28 91 95 10.1016/S0145-2126(03)00121-8 14630085 (Pubitemid 37433798)
32. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Nardinocchi L, Puca R, Sacchi A, D'Orazi G, Mol Cancer 2009 8 1 19128456
33. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH, Mol Cancer Ther 2008 7 1961 1973 10.1158/1535-7163.MCT-08-0198 18645006
34. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH, Cancer Res 2009 69 2400 2407 10.1158/0008-5472.CAN-08-4312 19276344
35. Effects of recombinant erythropoietin on breast cancer-initiating cells. Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F, Neoplasia 2007 9 1122 1129 10.1593/neo.07694 18084619 (Pubitemid 350255350)
36. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI, Blood 2004 103 3503 3510 10.1182/blood-2003-07-2340 14670925 (Pubitemid 38525684)
37. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI, Blood 2008 111 2220 2229 10.1182/blood-2007-07-102632 18039953 (Pubitemid 351451536)
38. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, Cramer T, PLoS One 2010 5 12038 10.1371/journal.pone.0012038 20706634
39. Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, D'Avella D, Panchision DM, Della Puppa A, Scienza R, Basso G, Stem Cells 2010 28 1918 1929 10.1002/stem.518 20827750
40. Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells. Yu EZ, Li YY, Liu XH, Kagan E, McCarron RM, Lab Invest 2004 84 553 561 10.1038/labinvest.3700071 15064771 (Pubitemid 38858464)
41. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL, Clin Cancer Res 2007 13 2441 2448 10.1158/1078-0432.CCR-06-2692 17438103 (Pubitemid 46698595)
42. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L, Zhou Q, J Biol Chem 2009 284 10004 10012 10.1074/jbc.M805997200 19211554